Goldman Sachs’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

Goldman Sachs’s Portfolio CBMG Stock Details CBMG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-12,249	Closed	-$225K	–	6565
2020 Q4	$225K	Buy	+12,249	New	+$223K	﹤0.01%	5034
2018 Q2	–	Sell	-52,843	Closed	-$927K	–	6162
2018 Q1	$927K	Buy	+52,843	New	+$967K	﹤0.01%	4104
2017 Q3	–	Sell	-61,733	Closed	-$540K	–	6967
2017 Q2	$540K	Buy	+61,733	New	+$544K	﹤0.01%	5034
2016 Q3	–	Sell	-18,703	Closed	-$224K	–	7263
2016 Q2	$224K	Buy	+18,703	New	+$300K	﹤0.01%	5609
2015 Q1	–	Sell	-11,798	Closed	-$152K	–	7372
2014 Q4	$152K	Sell	11,798 -8,252	-41%	-$126K	﹤0.01%	6353
2014 Q3	$421K	Buy	+20,050	New	+$409K	﹤0.01%	5435

Goldman Sachs's CBMG Position: Q1 2021 in Review

Goldman Sachs sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q1 2021, closing a stake of 12,249 shares — an estimated $225K sold.

Goldman Sachs first reported a position in CBMG in Q3 2014 and held it in 6 quarters. The position peaked at $927K in Q1 2018. 0 funds tracked by Wall St. Rank hold CBMG as of Q1 2021.

Goldman Sachs reported no remaining Cellular Biomedicine Group, Inc. position as of Q1 2021 after selling out during the quarter.
Goldman Sachs sold 12,249 Cellular Biomedicine Group, Inc. shares in Q1 2021, an estimated $225K.
Goldman Sachs first reported a position in Cellular Biomedicine Group, Inc. in Q3 2014 and held it in 6 quarters.
Goldman Sachs's Cellular Biomedicine Group, Inc. position peaked at $927K in Q1 2018.
0 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q1 2021.

Based on Goldman Sachs's 13F filing for Q1 2021, filed 17 May 2021.